Corinne Faivre-Finn – Impacts — Research Explorer The University of Manchester

Phone+44 (0) 161 446 8200/ 3302/ 3337 (Medical Lung Office), +44 (0) 161 918 7444 (Academic PA)
Emailcorinne.finnnhsnet, maria.moran3nhsnet (Medical PA), kellie.yu-2manchester.acuk (Academic PA)
Websitehttps://www.bmh.manchester.ac.uk/research, http://www.christie.nhs.uk/

The Christie NHS Foundation Trust, Wilmslow Road, Withington
M20 4BX Manchester
United Kingdom

If you made any changes in Pure these will be visible here soon.

5 results
- Title(descending)

Confirmation that prophylactic irradiation of tracts (PIT) is not justified in routine treatment of malignant pleural mesothelioma (MPM) meaning patients now do not receive unnecessary treatment
Corinne Faivre-Finn (Corresponding participant)
Impact: Health and wellbeing
Developing consensus guidelines on radiotherapy use during Covid-19 to reduce hospital attendances and risk of Covid infection to lung cancer patients
Corinne Faivre-Finn (Corresponding participant) & Kathryn Banfill (Participant)
Impact: Health and wellbeing
Establishing the evidence for treatment to improve outcomes in patients with lung cancer
Fiona Blackhall (Participant), Corinne Faivre-Finn (Participant), Paul Lorigan (Participant), Malcolm Ranson (Participant) & Nicholas Thatcher (Participant)
Impact: Health impacts
Our research as part of the international PACIFIC trial, led to the approval of a new treatment (Durvalumab) which improves progression free and overall survival in Stage III Non-small cell lung cancer (NSCLC)
Corinne Faivre-Finn (Corresponding participant)
Impact: Health and wellbeing
Radiotherapy research changes standard clinical practice and improves survival for patients with small-cell lung cancer
Corinne Faivre-Finn (Corresponding participant), Fiona Blackhall (Participant) & Paul Lorigan (Participant)
Impact: Health and wellbeing